Testing a new drug for advanced Parkinson's
Part of Brain & nervous system clinical trials.
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Parkinson's for at least 10 years
- Age between 50 and 80 years old
- Your Parkinson's symptoms are not well controlled with current treatments
- You are in Hoehn & Yahr stage 4 or 5 (severe disability) when your medication is not working
- You do not have dementia or significant memory problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients who previously received IPS101A, an experimental gene therapy treatment for severe Parkinson's disease. Researchers want to check how you're doing over time and gather information about the treatment's long-term effects.
This trial tests an experimental drug called MT101-5 for people recently diagnosed with Parkinson's disease. It aims to see if the drug is safe and can help control symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.